

Curriculum Vitae

Date Prepared: February 12, 2008

Name: Lisa Alison Prosser

Office Address: Center for Health Services Research
One Ford Place, 3A
Henry Ford Health System, Detroit, MI, 48202
Phone: 248-874-5485 FAX: 313-874-7137
Email: lprosse1@hfhs.org or lisa_prosser@hphc.org

Education:

1984-1988	B.A. Mathematics	Cornell University
1990-1992	M.S. Management	MIT Sloan School of Management
1990-1992	M.S. Technology & Policy	MIT
1995-2000	Ph.D. Health Policy	Harvard University

Academic Appointments:

1999-2000	Research Fellow	Harvard Medical School
2000-2001	Instructor	Harvard Medical School
2001-present	Assistant Professor	Harvard Medical School
2006-present	Assistant Professor (secondary appointment)	Harvard School of Public Health
2008-present	Research Scientist	Henry Ford Health System

Other Professional Positions:

1988-1990	Systems Consultant	Andersen Consulting
1991	Health Policy Analyst	Abt Associates
1992-1995	Health Care Consultant	The Wilkerson Group
1996-2000	Research Assistant	Program for the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis

Major Committee Assignments:

2002-2006	Chair, Subcommittee on Faculty Maternity Leave Policy (2002-2005) Joint Committee on the Status of Women, Harvard Medical School
2004	Special Reviewer, Research Grants Review Committee, National Eye Institute
2005	Co-Lead, Advisory Committee on Immunization Practices Influenza Working Group, Economic Subgroup, CDC
2005	Member, New Vaccines for Adolescents: National Stakeholders Meeting, CDC/NVAC
2005-present	Member, Database Advisory Panel, National Multiple Sclerosis Society
2006	Special Reviewer, Research Grants Review Committee, Decision, Risk and Management Sciences Program, National Science Foundation
2006-	Member, Committee on Higher Degrees in Health Policy, Harvard University
2006-	Member, ISPOR Fellowship Standards Task Force

- 2007 Member, Research Grants Review Committee, State of Pennsylvania Department of Health
 2007- DACP Faculty Search Committee

Professional Societies:

- 1996-present AcademyHealth, Member
 1996-present Society for Medical Decision Making, Member
 Abstract Reviewer (2000-2007)
 Abstract Scientific Review Committee Co-Chair (2008 Annual Meeting)
 2000-present International Health Economics Association
 2001-present International Society for Pharmacoeconomics and Outcomes Research, Member
 Abstract Reviewer (2002-2005)
 Contributed Workshops Co-Chair (2006 Annual International Meeting)
 2006-present American Society for Health Economists, Member

Editorial Positions:

- | | | |
|--------------|-----------------|--|
| 1997-present | Ad hoc reviewer | Journal of Health Economics |
| 1999 | Ad hoc reviewer | Evaluation and Program Planning |
| 1999 | Ad hoc reviewer | Medical Care |
| 2000 | Ad hoc reviewer | Annals of Internal Medicine |
| 2000 | Ad hoc reviewer | American Journal of Managed Care |
| 2001 | Ad hoc reviewer | Pharmacoeconomics |
| 2001 | Ad hoc reviewer | Future Drugs |
| 2001-present | Ad hoc reviewer | Medical Decision Making |
| 2003 | Ad hoc reviewer | Clinical Therapeutics |
| 2003-present | Ad hoc reviewer | Value in Health |
| 2004-present | Ad hoc reviewer | Vaccine |
| 2004 | Ad hoc reviewer | Expert Review of Pharmacoeconomics and Outcomes Research |
| 2004 | Ad hoc reviewer | American Journal of Managed Care |
| 2004 | Ad hoc reviewer | Pediatrics |
| 2005 | Ad hoc reviewer | Archives of Adolescent Medicine |
| 2005-present | Ad hoc reviewer | The Lancet |
| 2005 | Ad hoc reviewer | Epidemiologic Reviews |
| 2005 | Ad hoc reviewer | Journal of Pediatrics |
| 2006 | Ad hoc reviewer | AHRQ |
| 2006 | Ad hoc reviewer | Health Affairs |
| 2006 | Ad hoc reviewer | Arch Dermatology |
| 2006 | Ad hoc reviewer | Human Vaccines |
| 2007 | Ad hoc reviewer | Health Policy |

Awards and Honors:

- 1984-1988 Cornell Tradition Fellowship, Miller Scholarship in Mathematics, Newton North High School Music Department Scholarship, Sons of Italy Scholarship, National Merit Scholarship Semifinalist
 1991 Master's Thesis Travel Grant, MIT Program on the Pharmaceutical Industry

1992	William J. Stewart, Jr. Award for extracurricular leadership at MIT
1992	Technology & Policy Award in recognition of founding Women in Technology & Policy
1995-1997	National Library of Medicine Fellowship
1997-1999	National Multiple Sclerosis Society Doctoral Dissertation Fellowship
1998	Lee B. Lusted Student Prize, Society for Medical Decision Making
1999	National Cholesterol Outcomes Research Excellence (CORE) Award, first place
1999-2000	Thomas O. Pyle Fellowship, Harvard Pilgrim Health Care and Harvard Medical School
2002	50 th Anniversary Scholars in Medicine Award, Harvard Medical School
2005	Best General Podium Presentation, International Society for Pharmacoeconomics and Outcomes Research Annual Meeting

Research and Teaching Contributions

A. Narrative Report

My major research interests are (1) economic evaluations of health interventions and (2) valuation of health for economic evaluations. My current research focuses on policy-relevant topics concerning the cost-effectiveness of childhood interventions, such as a study of newborn screening for metabolic disorders that will assess how the inclusion of stress and anxiety associated with false positive tests affects the cost-effectiveness of expanded newborn screening programs. My research on the economic impact of influenza vaccination has been used in setting national vaccine policy for children and for prioritizing subgroups in vaccine shortage years. A study underway that assesses public values for avoiding influenza illness will provide data on the relative importance preventing influenza in different age and risk groups.

Another goal in my research is to advance the methods of valuing health for cost-effectiveness analysis, particularly for children's health states. A current project is testing new approaches for valuing temporary health states using a discrete choice experiment.

B. Funding Information

1997-1999	National MS Society (dissertation fellowship)	Doctoral Student	Cost-effectiveness of interferon beta-1a, interferon beta-1b and glatiramer acetate in patients with relapsing-remitting multiple sclerosis
2000-2002	CDC (through ACHP)	Co-Investigator	Cost-effectiveness of pneumococcal conjugate vaccine
2001-2002	CDC (through VSD)	Co-Investigator	Economic analysis of strategies to reduce influenza morbidity in children
2001-2004	CDC (through ATPM)	Co-Investigator	Costs and cost-effectiveness of administering influenza vaccination in non-traditional settings (Joint Initiative in Vaccine Economics)

2001-2004	AHRQ	Co-Investigator	RCT to reduce prescribing errors in hypertension
2002-2003	PhRMA Foundation	Principal Investigator	Are managed care decisions consistent with public preferences?
2003-2006	ELSI/NIH	Co-Investigator	Expanded newborn screening for metabolic disorders
2003-2006	NICHHD	Co-Investigator	Decision analysis of otitis media vaccination strategies
2004-2007	CDC	Co-Investigator	Joint Initiative in Vaccine Economics II
2004-2007	CDC	Consultant	Health values and treatment of pediatric type 2 diabetes
2005-2006	DACP Faculty Grant	Principal Investigator	Valuing children's health: A review of cost-effectiveness analyses for pediatric health interventions
2005-2006	CDC	Principal Investigator	Child maltreatment quality of life measurement tool
2005-2006	NLM/NIH	Co-Investigator	Methods for evaluating bioterrorism
2005-2010	NICHHD	Co-Investigator	Improving primary care to prevent childhood obesity
2006-2007	BSFC	Co-Investigator	Combining clinical effectiveness and cost effectiveness
2006-2007	HPHC Foundation	Principal Investigator	Economic barriers to obesity prevention and management in children
2007-2008	CDC	Principal Investigator	Cost-effectiveness of live attenuated influenza vaccine for children
2007-2010	CDC	Co-Investigator	Joint Initiative in Vaccine Economics III

C. Report of Current Research Activities

Title: Expanded newborn screening for metabolic disorders

Description: Cost-effectiveness analysis of expanded newborn screening program for metabolic disorders. Study will include costs of false positives and will measure health-related quality-of-life for treatments and outcomes.

Role: Co- investigator

Title: Decision analysis of otitis media vaccination strategies

Description: Decision analytic model that uses empirical cohort data and computer simulation to evaluate alternative strategies for otitis media vaccination to identify how further investment in research can best influence future policy decisions.

Role: Co-investigator

Title: Joint Initiative in Vaccine Economics II

Description: A series of economic studies that will inform policy decisions about new vaccines and vaccine delivery programs, including an online discrete choice experiment to value influenza-related health outcomes (lead investigator) and a utility assessment project for varicella zoster outcomes in the elderly (co-investigator).

Role: Co-investigator

Title: Health values and treatment of pediatric type 2 diabetes

Description: A study to assess and compare the preferences of adolescents with type 2 diabetes or prediabetes and their parents for states of health impacted by type 2 diabetes.

Role: Consultant

Title: Methods for evaluating bioterrorism surveillance tools

Description: The development of tools to compare statistical methods for detection of bioterrorist attack using 1) weighted ROC curves; 2) generalized multidimensional ROC surfaces; and 3) cost-based evaluation incorporating investigation and false positive costs as well as the value of mortality and morbidity incurred and averted by each method.

Role: Co-investigator

Title: Improving primary care to prevent childhood obesity

Description: A cluster-randomized controlled trial in 10 pediatric practices of a large multi-site group practice in eastern Massachusetts to evaluate the effectiveness and cost-effectiveness of an innovative, sustainable primary care practice change intervention to prevent obesity among young children.

Role: Co-investigator

Title: Combining clinical effectiveness and cost effectiveness

Description: This project will combine clinical and cost-effectiveness information in new technology appraisals that will enhance the ability of health care decision makers to define and prioritize the use of evidence-based best clinical practices and medical technologies.

Title: Economic barriers to obesity prevention and management in children

Description: This project will result in a better understanding of the economic tradeoffs parents make with respect to child food choices, activities, and other aspects of parenting that could affect child overweight.

Title: Cost-effectiveness of live attenuated influenza vaccine for children

Description: This project will evaluate the cost-effectiveness of live attenuated influenza vaccine incorporating the costs and quality of life effects associated with adverse events, wheezing and increased hospitalization, for younger children.

D. Report of Teaching

1. Local contributions

a. Courses

- 1996-1998 HSPH, Management Science, Teaching Assistant
6 graduate students, 4 hours per week, one-half semester.
- 1996 HSPH, Decision Analysis in Clinical Research, Teaching Assistant
40 graduate students, 4 hours per week, one-half semester.
- 1996 HSPH, Decision Analysis for Health and Medical Practices, Teaching Assistant
40 graduate students, 4 hours per week, one-half semester.
- 1997 HSPH, Decision Theory, Teaching Assistant
8 graduate students, 4 hours per week, one semester.
- 2003-2005 HSPH, Methods for Decision Analysis in Public Health and Medicine, Guest Lecturer
25 students, 6 hours.
- 2004-2007 Cost-Effectiveness and Cost-Benefit Analysis for Health Program Evaluation, Lecturer
40 graduate students, 6 hours.
- 2006 HSPH, Decision Analysis Methods in Public Health and Medicine, Primary Instructor
25 students, 14 hours per week, one-half semester.

b. Seminars

- 2000 Department of Ambulatory Care and Prevention, seminar:
Patient-specific factors in clinical decision-making: the relationship between risk attitude and treatment choice in patients with multiple sclerosis
- 2000 Harvard Center for Risk Analysis, Preference Working Group seminar:
Patient preferences for treatments and health states in multiple sclerosis
- 2001 Department of Family and Preventive Medicine, UCSD, seminar:
Introduction to methods for decision analysis in health
- 2002 Dana Farber/ Harvard Cancer Center Outcomes Research Seminar:
Preferences for outcomes prevented by pneumococcal conjugate vaccine:
challenges in using parents as proxies for valuing children's health states
- 2002 Department of Ambulatory Care and Prevention/Pharmaceutical Policy Research
Seminar:
Cost-effectiveness of cholesterol-lowering interventions: challenges of using CEA in
decision-making
- 2003 Department of Ambulatory Care and Prevention, seminar:
Economic analysis of strategies to reduce influenza morbidity in children
- 2004 Department of Ambulatory Care and Prevention, seminar:
Are managed care decisions consistent with public preferences?

- 2005 Department of Ambulatory Care and Prevention, seminar:
The economics of childhood vaccination
- 2006 Harvard Newborn Medicine Epidemiology and Clinical Medicine Conference
Economic values for newborn screening of metabolic disorders and related outcomes
- 2006 Dept. of Health Policy and Management, Harvard School of Public Health, seminar:
Should we vaccinate more children against influenza? Projected health benefits, risks,
and cost-effectiveness
- 2006 Department of Ambulatory Care and Prevention, seminar:
Expanded newborn screening: The effect of false positive test results on quality of life

c. Continuing Medical Education Courses

- 2003-2005 Cost-effectiveness Analysis for Medical Technologies and Pharmaceuticals, Lecturer
40 students, 6 hours

Regional Contributions

Invited Presentations:

- 2006 Annual Meeting of the New England Consortium of Metabolic Programs
Cost-effectiveness of expanded newborn screening

National Contributions

Invited Presentations:

- 2000 Annual Meeting of the Society for Medical Decision Making
Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in
multiple sclerosis (podium presentation)
- 2001 Annual Meeting of the Society for Medical Decision Making
Do risk attitudes differ across domains and respondent types? (podium presentation)
- 2003 Advisory Committee on Immunization Practices, Centers for Disease Control and
Prevention:
Economic analysis of strategies to reduce influenza morbidity in children (presentation)
- 2003 National Immunization Program, Centers for Disease Control and Prevention:
Economic analysis of strategies to reduce influenza morbidity in children (seminar)
- 2004 Ninth Annual Meeting of the International Society for Pharmacoeconomics and
Outcomes Research
An economic analysis of rapid tests and antiviral treatments for influenza in children
(podium presentation)

- 2005 Tenth Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Costs of delivering adult influenza vaccination in non-traditional settings (podium presentation)
- 2005 Advisory Committee on Immunization Practices Influenza Working Group
Using economic information to prioritize subgroups during influenza vaccine shortages (presentation)
- 2007 11th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes research
Measuring health preferences for use in cost-utility and benefit analyses of interventions in children: Theoretical and methodological considerations (podium presentation)
- 2007 Center for Health Services Research, Henry Ford Health System
Projected costs, risks, and benefits of influenza vaccination of children (seminar)
- 2007 Conference on Routine Vaccination Against Influenza for Older Children, Centers for Disease Control and Prevention
Projected health benefits, risks, and cost-effectiveness of influenza vaccination: Children aged 5-17 years (presentation)
- 2007 Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention
Cost-effectiveness of influenza vaccination: updated estimates for children aged 2-4 years (presentation)

International Contributions

Invited Presentations:

- 2007 Initiative on Medication Management, Policy Analysis, Research & Training (IMPART), Dalhousie University, Halifax, Nova Scotia, Canada
Introduction to Markov models (seminar/workshop)

Bibliography

Original Articles

1. **Prosser LA**, Koplan JP, Neumann PJ, Weinstein MC. Barriers to using cost-effectiveness analysis in managed care decision making. *Am J Manag Care*. 2000;6(2):173-179.
2. **Prosser LA**, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. *Ann Intern Me*. 2000;132(10):768-779.
3. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. The relationship between risk attitude and treatment choice in patients with relapsing-remitting multiple sclerosis. *Med Decis Making*. 2002;22:506-513.
4. Lieu TA, Thompson KM, **Prosser LA**, O'Brien MA, Yusuf HR, Shefer AM, Weinstein MC, Rickert DL. Emerging issues in vaccine economics: perspectives from the USA. *Expert Rev Vaccines*. 2002;1(4):433-442.
5. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Patient and community preferences for treatments and health states in multiple sclerosis. *Mult Scler*. 2003;9:311-319.
6. Wang SJ, Middleton B, **Prosser LA**, Bardon CG, Spurr CD, Carchidi PJ, Kittler AF, Goldszer RC, Fairchild DG, Sussman AJ, Kuperman GJ, Bates DW. A cost-benefit analysis of electronic medical records in primary care. *Am J Med*. 2003;114(5):397-403.
7. **Prosser LA**, Ray GT, O'Brien M, Kleinman K, Santoli J, Lieu TA. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine. *Pediatrics*. 2004;113(2):283-290.
8. **Prosser LA**, Kuntz KM, Bar-Or A, Weinstein MC. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis. *Value Health*. 2004;7(5):554-568.
9. **Prosser LA**, Bridges CB, Uyeki TM, Rego VH, Ray GT, Meltzer MI, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Values for preventing influenza-related morbidity and vaccine adverse events in children. *Health Qual Life Outcomes*. 2005;3(18):1-16.
10. Simon SR, Majumdar SR, **Prosser LA**, Salem-Schatz S, Warner C, Kleinman K, Miroshnik I, Soumerai SB. Group versus individual academic detailing to improve the use of antihypertensive medications in primary care: a cluster-randomized controlled trial. *Am J Med*. 2005;118(5):521-528.
11. Gupta RS, Bewtra M, **Prosser LA**, Finkelstein JA. Predictors of hospital charges for children admitted with asthma. *Ambul Pediatr*. 2006;6(1):15-20.
12. Wittenberg E, Halpern E, Divi N, **Prosser LA**, Araki SS, Weeks JC. The effect of age, race and gender on preference scores for hypothetical health states. *Qual Life Res*. 2006;15(4):645-653.

13. Skelding PC, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, **Prosser LA**, Simon SR. Clinical and non-clinical correlates of adherence to prescribing guidelines for hypertension in a large managed care organization. *J Clin Hypertension*. 2006;8(6):414-419.
14. **Prosser LA**, Bridges CB, Uyeki TM, Hinrichsen VL, Meltzer MI, Molinari NA, Schwartz B, Thompson WW, Fukuda K, Lieu TA. Health benefits, risks, and cost-effectiveness of influenza vaccination of children. *Emerg Infect Dis*. 2006;12(10):1548-1558.
15. Eisenberg DM, Post DE, Davis RB, Connelly MT, Legedza AT, Hrbek AL, **Prosser LA**, Buring JE, Cherkin DC. Addition of choice of complementary therapies to usual care for acute low back pain: a randomized controlled trial. *Spine*. 2007;32(2):151-8.
16. Simon SR, Rodriguez HP, Majumdar SR, Kleinman K, Warner C, Salem-Schatz S, Miroshnik I, Soumerai SB, **Prosser LA**. Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications. *J Clin Hyper*. 2007;9(1):15-20.
17. **Prosser LA**, Wittenberg E. Do risk attitudes differ across domains and respondent types? *Med Decis Making*. 2007;27(3):281-287.
18. **Prosser LA**, O'Brien MA, Molinari NA, Hohman KH, Nichol KL, Wortley PM, Messonnier ML, Lieu TA. Cost-effectiveness of delivering adult influenza vaccination in non-traditional settings. *Pharmacoeconomics*. 2008;26(2):163-178.
19. Lieu TA, Ortega-Sanchez I, Ray GT, Rusinak D, Yih WK, Choo PW, Shui I, Kleinman K, Harpaz R, **Prosser LA**. Community and patient values for preventing zoster. *Pharmacoeconomics*. In press.
20. **Prosser LA**, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance for false-positive newborn screening results. *Arch Pediatr Adolesc Med*. In press.

Review Articles

1. **Prosser LA**, Corso PS. Measuring health-related quality of life for child maltreatment: A systematic literature review. *Health Qual Life Outcomes*. 2007;5(1)1-17. Available at: <http://www.hqlo.com/content/5/1/42>.
2. **Prosser LA**, Hammitt JK, Keren R. Measuring health preferences for use in cost-utility and benefit analyses of interventions in children: Theoretical and methodological considerations. *Pharmacoeconomics*. 2007;25(9):713-726.
3. Ladapo JA, Neumann PJ, Keren R, **Prosser LA**. Valuing children's health: a comparison of cost-utility analyses for adult and pediatric health interventions. *Pharmacoeconomics*. 2007;25(10):817-828.
4. Ortega-Sanchez IR, Lee GM, Jacobs RJ, **Prosser LA**, Molinari NA, Zhang X, Baine WB, McCauley MM, Miller T. Projected cost-effectiveness of new vaccines for adolescents in the United States. *Pediatrics*. 2008;121 Suppl 1:S63-78.

Letters

1. **Prosser LA**, Stinnett AA, Goldman L, Weinstein MC. Cost-effectiveness analyses. *Ann Intern Med* 2001;135(5):383.
2. **Prosser, LA**, Lieu TA. Comments on the Prosser et al approach to value disease reduction in children: In reply. *Pediatrics*. 2004;114:1375-1376.

Theses

1. **Prosser LA**. Pharmaceutical research and development: the effects of increased competition on human resource strategies [master's thesis]. Boston (MA): MIT; 1992.
2. **Prosser LA**. Patient preferences and economic considerations in treatment decisions for multiple sclerosis [dissertation]. Cambridge (MA): Harvard University; 2000.

Abstracts

1. **Prosser LA**, Uyeki TM, Bridges CB, Rego VH, Meltzer M, Schwartz B, Thompson WW, Fukuda K, Lieu TA. An economic analysis of rapid tests and antiviral treatments for influenza in children. *Value in Health*. 2004;3:222-223.
2. **Prosser LA**, Concannon TW, Pearson SD, Hammitt JK. An internet survey of public preferences for characteristics of health interventions. *Med Decis Making*. 2005;25(1):E57.
3. **Prosser LA**, Griffin M, Keren R, Meltzer MI, Ortega-Sanchez I, Herrera G, Messonnier ML, Bridges CB. Using economic evidence to prioritize subgroups during an influenza vaccine shortage. *Med Decis Making*. 2006;26(1):E77.
4. **Prosser LA**, Wittenberg E. Valuing children's health: response issues with using parents as proxies. *Med Decis Making* 2007;25(1):E57.
5. **Prosser LA**, Kong J, Rusinak D, Waisbren SE. Waisbren. Expanded newborn screening: the effect of preferences for false positive test results and dietary treatments on cost-effectiveness. *Med Decis Making*. 2008;25(1):E60.
6. Sandberg EA, **Prosser LA**, Neumann P, Weinstein MC. Health state utilities in children ages 7-10 with attention deficit hyperactivity disorder. *Med Decis Making*. 2008;25(1):E72.